Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) EBT Margin (2016 - 2025)

IGC Pharma (IGC) has disclosed EBT Margin for 16 consecutive years, with 953.4% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 53666.0% to 953.4% in Q3 2025 year-over-year; TTM through Sep 2025 was 582.82%, a 47965.0% increase, with the full-year FY2025 number at 560.27%, up 40628.0% from a year prior.
  • EBT Margin was 953.4% for Q3 2025 at IGC Pharma, down from 487.5% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 362.73% in Q1 2025 to a low of 7757.14% in Q3 2021.
  • A 5-year average of 1847.1% and a median of 977.97% in 2024 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 723512bps in 2021; the steepest drop was -643154bps in 2021.
  • IGC Pharma's EBT Margin stood at 1676.76% in 2021, then soared by 60bps to 677.41% in 2022, then crashed by -304bps to 2739.71% in 2023, then skyrocketed by 74bps to 711.67% in 2024, then tumbled by -34bps to 953.4% in 2025.
  • Per Business Quant, the three most recent readings for IGC's EBT Margin are 953.4% (Q3 2025), 487.5% (Q2 2025), and 362.73% (Q1 2025).